← brief for 2026-09-03 · Slowing decline

Type 2 diabetes and chronic kidney disease combinations in heart failure across the ejection fraction spectrum: clinical associations, medication use, and cause-specific outcomes: a contemporary, real-world analysis of the Swedish Heart Failure Registry.

Key takeaways

Sweden tracks nearly everyone treated for heart failure, and this analysis covered 54,341 patients from 2017 to 2023, average age 73, and 34% women. Half had neither kidney disease nor type 2 diabetes, and about a quarter had kidney disease alone. The study compared which heart medicines each group actually received, and how often they died, went to hospital for heart failure, or reached kidney failure. It is observational, so the differences between groups show links, not proof that one condition or drug caused the outcome.

Who did this work

Ferrannini G (Cardiology Unit, Department of Medicine, Karolinska Institutet, Eugeniavägen 27, Stockholm 17164, Sweden.) · Pol T (Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.) · Ljungman C (Institute of Medicine Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.) · Dahlström U (Department of Cardiology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.) · Merolla A (Cardiology Unit, Department of Medicine, Karolinska Institutet, Eugeniavägen 27, Stockholm 17164, Sweden.) · Lund LH (Cardiology Unit, Department of Medicine, Karolinska Institutet, Eugeniavägen 27, Stockholm 17164, Sweden.)

Source

Paper · Europe PMC, CKD · 2026-09-02
https://doi.org/10.1093/ejhf/xuag249